Browsing by Author "Lopes, Gilberto de Lima"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarkerPublication . Aguiar, Pedro N., Jr.; Santoro, Ilka Lopes; Tadokoro, Hakaru; Lopes, Gilberto de Lima; Filardi, Bruno Andraus; Oliveira, Pedro; Castelo-Branco, Pedro; Mountzios, Giannis; de Mello, Ramon AndradeBackground: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
- Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-AnalysisPublication . De Mello, Ramon Andrade; Aguiar, Pedro, Jr.; Cabral, Paloma; Chaves, Fablo; Liu, Davi; Soares, João Paulo; Mountzios, Giannis; Tadokoro, Hakaru; Lopes, Gilberto de Lima
- Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targetsPublication . Aguiar, Pedro Nazareth; De Mello, Ramon Andrade; Noia Barreto, Carmelia Maria; Perry, Luke Alastair; Penny-Dimri, Jahan; Tadokoro, Hakaru; Lopes, Gilberto de LimaLung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of nonsmall cell lung cancer (NSCLC) after failure of platinumbased therapy. One recent study has demonstrated that ICI monotherapy was superior to platinum-based chemotherapy for first-line treatment. Nevertheless, this benefit was only for a minority of the population (30%) whose tumour programmed death receptor ligand-1 (PD-L1) expression was above 50%. Therefore, several strategies are under investigation. One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets. However, all of these combinations are at an early stage of investigation and may be very expensive or toxic, producing several harmful adverse events.
- The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysisPublication . Jr., Pedro N. Aguiar; Santoro, Ilka Lopes; Tadokoro, Hakaru; Lopes, Gilberto de Lima; Filardi, Bruno Andraus; Oliveira, Pedro; Mountzios, Giannis; de Mello, Ramon AndradeBackground: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.